查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1809911

IgA肾臟病市场（按药物类别、治疗方法、患者类型、最终用户和分销管道）—2025 年至 2030 年全球预测

IgA Nephropathy Market by Drug Class, Treatment, Patient Type, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

IgA肾臟病市场预计 2024 年将达到 13 亿美元，2025 年将达到 13.7 亿美元，2030 年将达到 18.5 亿美元，复合年增长率为 6.10%。

主要市场统计数据
基准年2024年 13亿美元
预计2025年 13.7亿美元
预测年份 2030 18.5亿美元
复合年增长率（%） 6.10%

IgA肾臟病，通常称为伯杰氏病，是全球最常见的原发性肾丝球肾炎。含有免疫球蛋白A的免疫复合物沉积于肾系膜，引发连锁发炎反应、系膜增生，最终导致肾丝球疤痕形成。这种异质性疾病的临床频谱广泛，从无症状性的镜下血尿到迅速进展至末期肾病，对患者和医疗基础设施带来沉重负担。

随着我们理解的不断加深，我们越来越清楚地认识到，早期诊断、分层风险评估和有针对性的治疗性介入对于减缓疾病进展至关重要。目前的治疗模式主要依赖血管收缩素转化酵素抑制剂和血管收缩素受体阻断剂来降低蛋白尿，并在​​高风险病例中辅以免疫抑制剂。然而，儘管采取了这些措施，仍存在未满足的需求，包括实现持久缓解、最大限度地减少副作用以及根据患者个别情况制定治疗方案。

IgA肾臟病的全球盛行率存在地域差异，亚洲人群的发生率高于西方人群。这种差异凸显了全面临床试验设计的必要性，以及针对不同地区制定治疗可近性和报销方案的重要性。此外，新兴的生物标记研究和基因组分析的进展凸显了个人化医疗的发展方向，并有望优化患者选择并改善疗效。

本执行摘要整合了最新的临床数据、技术创新和影响IgA肾臟病格局的监管格局，旨在应对这些复杂问题。透过严谨的分析，我们得以洞察不断发展的治疗方法、诊断进展和相关人员的动态，从而帮助决策者把握机会，优化策略倡议。

诊断的进步和治疗方法的革命性变化正在重新定义 IgA肾臟病的治疗前景和研究轨迹

近年来，由于诊断准确性的提高和治疗方法的创新，IgA肾臟病的现状发生了显着变化。以往，临床医生依靠侵入性肾臟切片检查来确认疾病活动，而现在他们能够获得新的生物标记物，例如血清半乳糖缺乏切片检查IgA1 浓度和尿液细胞激素激素谱。这些工具有助于更早实施更个人化的干预措施，从而可能重塑患者分层并改善长期疗效。

评估2025年美国关税调整对全球供应链、药品价格和IgA肾臟病治疗可及性的深远影响

美国计划于2025年宣布新的关税，将对全球医药供应链造成重大干扰。来自主要製造地的活性药物原料药可能面临进口关税上调，这将对生产成本产生连锁反应，并最终影响药品价格。鑑于肾臟病治疗药物的净利率已受到严格审查，这些调整可能会降低盈利并限制患者的用药管道。

对 IgA肾臟病治疗动态的策略性洞察，涵盖药物类别、治疗方案、患者类型、最终用户和分销管道

多层次細項分析揭示了IgA肾臟病市场多样化的治疗和护理动态。依药物类别划分，血管张力素转换酶（ACE）抑制剂和血管收缩素受体阻断剂与免疫抑制剂（例如Azathioprine、皮质类固醇、Cyclophosphamide和Mycophenolate Mofetil）并存。单株抗体处于领先地位，致力于提供针对潜在免疫病理的标靶作用机制。

IgA肾臟病治疗生态系的地区差异凸显了医疗保健基础设施、获取机制和采用模式的差异

IgA肾臟病治疗的地区差异反映了医疗基础设施、报销框架和治疗方法采用模式的差异。在美洲，强大的透析网络和先进的移植项目得到了结构化保险体系的支持，这些体係有助于患者获得成熟和新兴的治疗方法。电子健康记录与基于价值的合约倡议的整合进一步简化了护理协调和疗效衡量。

大型製药企业的策略性倡议和竞争地位塑造了 IgA肾臟病治疗创新的未来

大型製药和生技公司正在积极调整其投资组合，以抓住IgA肾臟病领域的机会。现有的全球性公司正在利用其免疫学专业知识来推进单株抗体候选药物研发，并经常透过策略性收购和授权协议来补充其内部研发管线。对早期研究合作的投资凸显了他们致力于发现新标靶和加速转化研究的决心。

为行业领导者提供主动策略和战术性建议，以利用 IgA肾臟病药物开发的发展趋势

为了充分利用IgA肾臟病领域不断发展的机会，业界领导者应优先投资精准诊断和生物标记检验，以加强患者选择和治疗监测。建立整合临床、监管和商业专业知识的跨职能团队，可以简化研发週期并优化资源配置。

结合专家访谈、二次研究和数据三角测量的综合方法，为 IgA肾臟病市场的动态提供了可靠的见解

该分析以一套严谨的方法论为基础，该方法论整合了对关键意见领袖、临床专家和市场相关人员进行深入访谈所获得的定性见解。二次研究则有系统地查阅了同行评审期刊、临床试验註册中心、监管备案文件和公开的企业资料，从而构建了全面的信息库。

主要研究结果综合强调了协作创新和策略合作的迫切性，以推动 IgA肾臟病的治疗发展

本执行摘要中提出的证据凸显了IgA肾臟病管理中协作创新的迫切性。精准诊断、标靶免疫疗法和数位健康平台的出现，相关人员提供了前所未有的工具，以重新定义患者照护并改善长期肾臟预后。然而，要实现这一潜力，需要齐心协力，缩小可及性差距，简化临床开发流程，并协调整个医疗生态系统的奖励。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 标靶补体抑制剂在治疗领域的快速引入
  • 扩大非侵入性生物标记诊断将改变患者管理
  • 透过整合人工智慧驱动的影像平台增强疾病监测
  • 个人化治疗流程的出现，可以优化高风险患者的治疗结果
  • 监管部门对新型生技药品的推动塑造了治疗格局
  • 战略伙伴关係加速口服非类固醇药物的开发
  • 不断发展的报销模式支持 IgA肾臟病护理途径的早期疗育
  • IgA肾臟病治疗临床试验中病患报告结果的重要性日益增加

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

8. IgA肾臟病市场（依药物类别）

  • 血管紧张素转换酶抑制剂
  • 血管收缩素素受体阻断剂
  • 免疫抑制剂
    • Azathioprine
    • 皮质类固醇
    • Cyclophosphamide
    • Mycophenolate Mofetil
  • 单株抗体

9. IgA肾臟病市场（依治疗）

  • 透析
  • 免疫抑制治疗
  • 肾臟移植
  • 非免疫抑制治疗
  • 血浆置换

第 10 章 IgA肾臟病市场（依患者类型）

  • 成人
  • 老年患者
  • 儿科患者

第 11 章 IgA肾臟病市场（按最终用户）

  • 家庭医疗保健
  • 医院
  • 研究机构
  • 专科诊所

第 12 章 IgA肾臟病市场（按分销管道）

  • 线下药局
    • 医院药房
    • 零售药局
  • 网路药局

13.美洲IgA肾臟病市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 欧洲、中东和非洲IgA肾臟病市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

15. 亚太地区IgA肾臟病变市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Alnylam Pharmaceuticals, Inc.
    • Apellis Pharmaceuticals Inc.
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH.
    • Calliditas Therapeutics AB by Asahi Kasei Corporation
    • ChemoCentryx, Inc. by Amgen Inc.
    • Eledon Pharmaceuticals Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Ionis Pharmaceuticals Inc
    • Keymed Biosciences Inc.
    • Novartis AG
    • NovelMed Inc.
    • Novo Nordisk A/S.
    • Omeros Corporation
    • Otsuka Pharmaceutical Co. Ltd
    • Q32 Bio Inc.
    • Takeda Pharmaceutical Company
    • Travere Therapeutics Inc
    • Vera Therapeutics Inc
    • Vertex Pharmaceuticals Incorporated

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-3E7318E83176

The IgA Nephropathy Market was valued at USD 1.30 billion in 2024 and is projected to grow to USD 1.37 billion in 2025, with a CAGR of 6.10%, reaching USD 1.85 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.30 billion
Estimated Year [2025] USD 1.37 billion
Forecast Year [2030] USD 1.85 billion
CAGR (%) 6.10%

IgA nephropathy, commonly referred to as Berger's disease, is the most prevalent form of primary glomerulonephritis worldwide. It results from the deposition of immunoglobulin A-containing immune complexes in the renal mesangium, triggering a cascade of inflammation, mesangial proliferation, and eventual glomerular scarring. This heterogenous disease manifests a broad clinical spectrum, ranging from asymptomatic microscopic hematuria to rapid progression toward end-stage renal disease, placing immense strain on patients and healthcare infrastructures alike.

As our understanding deepens, it has become apparent that early diagnosis, stratified risk assessment, and targeted therapeutic interventions are critical to delaying disease progression. Current treatment paradigms rely heavily on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers to mitigate proteinuria, supplemented by immunosuppressive agents for high-risk cases. Yet, despite these measures, unmet needs persist in achieving sustained remission, minimizing adverse effects, and tailoring regimens to individual patient profiles.

The global prevalence of IgA nephropathy has shown geographic variability, with higher incidence observed in Asian populations compared to Western cohorts. This divergence underscores the importance of region-specific approaches to treatment access and reimbursement, as well as the need for inclusive clinical trial designs. Moreover, emerging biomarker research and advances in genomic profiling highlight the trajectory toward personalized medicine, promising to refine patient selection and improve outcomes.

To address these complexities, this executive summary synthesizes the latest clinical data, technological innovations, and regulatory developments shaping the IgA nephropathy landscape. Through rigorous analysis, critical insights emerge on evolving therapeutic approaches, diagnostic enhancements, and stakeholder dynamics, enabling decision-makers to navigate opportunities and optimize strategic initiatives.

Revolutionary Shifts in Diagnostic Advancements and Therapeutic Modalities Redefine the IgA Nephropathy Treatment Landscape and Research Trajectory

Recent years have witnessed a profound transformation in the IgA nephropathy landscape, driven by advances in diagnostic precision and therapeutic innovation. Once reliant on invasive renal biopsies to confirm disease activity, clinicians now have access to novel biomarkers such as serum galactose-deficient IgA1 concentrations and urinary cytokine profiles. These tools are reshaping patient stratification and enabling earlier, more personalized interventions that have the potential to improve long-term outcomes.

Simultaneously, the therapeutic paradigm is shifting toward targeted immunomodulation. Following the success of monoclonal antibodies in other autoimmune conditions, several pipeline candidates are advancing into late-stage clinical development. These agents aim to interrupt key pathways in IgA-mediated inflammation, offering the promise of disease modification beyond conventional corticosteroids and cytotoxic agents. Such targeted approaches are complemented by next-generation immunosuppressants that seek to balance efficacy with a reduced adverse-event profile.

Digital health solutions are also emerging as a critical component of patient management. Remote monitoring platforms, artificial intelligence-driven imaging analytics, and telemedicine support integrated care pathways that empower patients and streamline clinical workflows. Furthermore, collaborative frameworks among payors, providers, and patient advocacy groups are accelerating access models for innovative treatments.

As these developments converge, the IgA nephropathy landscape is poised for a new era of precision medicine. Stakeholders who embrace these transformative shifts will be well positioned to deliver enhanced patient outcomes, optimize resource allocation, and capture value in this dynamic field.

Evaluating the Far-Reaching Consequences of United States 2025 Tariff Adjustments on Global Supply Chains, Drug Pricing, and Access to IgA Nephropathy Treatments

The announcement of new United States tariff measures scheduled for 2025 introduces a pivotal disruptor to global pharmaceutical supply chains. Active pharmaceutical ingredients sourced from leading manufacturing hubs may face increased import duties, cascading through production costs and influencing final drug pricing. For therapies addressing IgA nephropathy, where margins are already under scrutiny, these adjustments threaten to erode profitability and impose constraints on patient access.

Manufacturers are evaluating mitigation strategies, including geographic diversification of API sourcing and onshore capacity expansion. However, these initiatives require significant capital investment and extended timelines, potentially delaying the commercialization of emerging monoclonal antibodies and novel immunosuppressants. Pharmaceutical distributors and wholesalers must also navigate revised logistics expenses, which could lead to altered contract terms with providers and payors.

Payor organizations are anticipated to intensify formulary management and reimbursement assessments in light of cost pressures. They may negotiate more aggressive pricing concessions or increase utilization controls, further impacting therapy uptake. In parallel, regulatory agencies are exploring mechanisms to offset tariff impacts, such as expedited review pathways and targeted subsidies for critical drug classes.

In this context, industry participants must adopt a proactive stance to assess the cumulative financial and operational effects of these tariff measures. Scenario planning, stakeholder collaboration, and policy advocacy will be essential to safeguard both commercial interests and patient access to life-altering IgA nephropathy treatments.

Strategic Insights into IgA Nephropathy Care Dynamics Spanning Drug Classes, Treatment Options, Patient Types, End Users, and Distribution Channels

A multifaceted segmentation analysis illuminates the diverse therapeutic and care dynamics within the IgA nephropathy market. In the domain of drug classes, the foundational reliance on ACE inhibitors and angiotensin receptor blockers continues to coexist with immunosuppressants such as azathioprine, corticosteroids, cyclophosphamide, and mycophenolate mofetil. At the frontier, monoclonal antibodies endeavor to offer targeted mechanisms of action that address underlying immunopathology.

Treatment modalities display significant heterogeneity, spanning chronic dialysis, immunosuppressive therapy protocols, kidney transplant interventions, non-immunosuppressive supportive therapies, and plasmapheresis procedures. Each treatment corridor presents distinct efficacy profiles, resource requirements, and patient tolerance considerations.

Patient demographics further shape demand patterns, with adult populations constituting the majority of cases, while elderly and pediatric patients require tailored approaches to dosing, comorbidity management, and safety monitoring. End-user settings reflect a wide distribution of care delivery, encompassing home healthcare programs, hospital inpatient and outpatient units, dedicated research institutes, and specialized nephrology clinics that are optimizing care coordination.

Distribution channels influence accessibility and patient engagement, with offline pharmacies-comprising both hospital-based dispensaries and retail outlets-remaining the primary access point for most therapies, complemented by growing adoption of online pharmacy services. This comprehensive segmentation perspective underscores the necessity for strategic alignment of product portfolios, service delivery models, and market access planning to address the full spectrum of stakeholder needs.

Regional Disparities in IgA Nephropathy Treatment Ecosystems Highlight Differing Healthcare Infrastructure, Access Mechanisms and Adoption Patterns

Regional dynamics in the IgA nephropathy arena reveal divergent patterns in healthcare infrastructure, reimbursement frameworks, and treatment adoption. In the Americas, robust dialysis networks and advanced transplant programs are supported by structured insurance systems that facilitate patient access to established and emerging therapies. Integration of electronic health records and value-based contracting initiatives further streamlines care coordination and outcome measurement.

Within Europe, the Middle East, and Africa, public health systems vary widely, driving disparities in the availability of high-cost interventions. Some European nations have embraced health technology assessments to inform coverage decisions for novel agents, while certain Middle Eastern and African markets remain constrained by budgetary limitations and limited local production of biologics.

Asia-Pacific markets are characterized by rapid growth in disease awareness and expanding clinical trial activity, especially in East Asian countries with historically elevated incidence rates. Reimbursement policies are evolving to accommodate breakthrough therapies, though out-of-pocket expenses and regulatory heterogeneity pose challenges. In emerging economies, partnerships between local stakeholders and multinational companies are instrumental in fostering infrastructure development, knowledge transfer, and patient education programs.

These regional insights underscore the importance of customized market entry strategies and stakeholder engagement plans that address the unique policy landscapes, funding mechanisms, and care pathways in each geography.

Strategic Movements and Competitive Positioning of Leading Pharmaceutical and Biotech Entities Shaping the Future of IgA Nephropathy Treatment Innovations

Leading pharmaceutical and biotechnology companies are actively reconfiguring their portfolios to capture opportunities in the IgA nephropathy space. Established global players are leveraging their immunology expertise to advance monoclonal antibody candidates, often through strategic acquisitions or licensing agreements that supplement internal pipelines. Investment in early-phase research collaborations underscores a commitment to identifying novel targets and expediting translational studies.

Specialized biotech firms are positioning themselves as pioneers in precision nephrology, focusing on biomarkers and companion diagnostics to support differentiated clinical development programs. These organizations often engage academic partners to enhance trial design and access to patient cohorts, thereby de-risking clinical pathways and enriching data quality.

Competitive positioning is further influenced by regulatory milestones and orphan drug designations, which provide incentives such as market exclusivity and expedited review. Companies with global manufacturing footprints are optimizing supply chains to ensure seamless product availability across multiple regions, while those with virtual or consortium models emphasize flexibility and cost efficiency.

Collaborative alliances between industry, academic centers, and patient advocacy groups are accelerating knowledge exchange and facilitating real-world evidence generation. As these entities refine go-to-market strategies, differentiation will hinge on the integration of therapeutic efficacy, safety profiles, and holistic patient support services.

Proactive Strategies and Tactical Recommendations Empowering Industry Leaders to Capitalize on Evolving Trends in IgA Nephropathy Therapeutic Development

To capitalize on the evolving IgA nephropathy landscape, industry leaders should prioritize investment in precision diagnostics and biomarker validation to enhance patient selection and treatment monitoring. Establishing cross-functional teams that integrate clinical, regulatory, and commercial expertise will streamline development lifecycles and optimize resource allocation.

Engagement with payors early in the clinical development process is essential to define value propositions and negotiate innovative contracting models that align pricing with outcomes. Simultaneously, fostering partnerships with patient advocacy organizations can strengthen trial recruitment, amplify real-world data initiatives, and support adherence programs that improve long-term patient retention.

Diversifying supply chain footprints, including nearshoring and dual-sourcing APIs, will mitigate tariff-related risks and ensure continuity of supply. Companies should also explore digital health platforms for remote patient monitoring and telemedicine services that enhance access and reduce the burden on healthcare facilities.

Finally, fostering an agile organizational culture that embraces data analytics, cross-industry collaboration, and rapid iteration will position businesses to respond effectively to regulatory shifts, competitive pressures, and evolving patient needs. By adopting these proactive strategies, stakeholders can drive meaningful innovation, capture market opportunities, and deliver superior outcomes for individuals living with IgA nephropathy.

Comprehensive Methodology Combining Expert Interviews, Secondary Research, and Data Triangulation to Deliver Robust Insights into IgA Nephropathy Market Dynamics

This analysis is underpinned by a robust methodology that integrates qualitative insights from in-depth interviews with key opinion leaders, clinical experts, and market stakeholders. Secondary research encompassed a systematic review of peer-reviewed journals, clinical trial registries, regulatory filings, and publicly available corporate disclosures to construct a comprehensive intelligence base.

Data triangulation techniques were employed to reconcile disparate information sources, ensuring the veracity of clinical endpoints, regulatory developments, and strategic initiatives. Market dynamics were further validated through cross-comparison of regional reimbursement policies, treatment guidelines, and real-world evidence from healthcare databases.

An expert advisory panel provided ongoing validation of emerging trends and potential market disruptors, guiding scenario planning and sensitivity analyses. This collaborative approach facilitated the refinement of key assumptions and enabled the identification of high-impact opportunities across the IgA nephropathy continuum.

By combining rigorous secondary research, expert validation, and methodical data integration, this study delivers actionable insights that reflect the complexity of the IgA nephropathy ecosystem and support informed decision-making.

Synthesis of Key Findings Underscoring the Urgency for Collaborative Innovation and Strategic Alignment to Advance IgA Nephropathy Therapeutic Development

The collective evidence presented in this executive summary underscores the urgency for collaborative innovation in IgA nephropathy management. With the advent of precision diagnostics, targeted immunotherapies, and digital health platforms, stakeholders have unprecedented tools to redefine patient care and improve long-term renal outcomes. However, realizing this potential will require concerted efforts to bridge gaps in access, streamline clinical development, and align incentives across the healthcare ecosystem.

Tariff-related challenges, evolving reimbursement landscapes, and regional disparities further emphasize the need for adaptive strategies that address both commercial viability and patient-centric objectives. Companies must embrace agile operating models, engage proactively with regulatory and payor authorities, and invest in infrastructure that supports decentralized care and real-world evidence generation.

Ultimately, the future of IgA nephropathy therapeutics will be shaped by those who can integrate scientific innovation with market realities, forging partnerships that accelerate translation from bench to bedside. As the landscape continues to evolve, the insights contained herein offer a strategic foundation for decision-makers committed to advancing therapies that alleviate disease burden and enhance quality of life for patients worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rapid adoption of targeted complement inhibitors in IgA nephropathy therapy pipelines
  • 5.2. Expansion of noninvasive biomarker diagnostics transforming IgA nephropathy patient management
  • 5.3. Integration of AI-driven imaging platforms enhancing IgA nephropathy disease monitoring
  • 5.4. Emergence of personalized treatment algorithms optimizing outcomes for high-risk IgA nephropathy patients
  • 5.5. Regulatory momentum for novel biologics shaping IgA nephropathy therapeutic landscape
  • 5.6. Strategic partnerships accelerating development of oral nonsteroidal agents in IgA nephropathy
  • 5.7. Evolving reimbursement models supporting early intervention in IgA nephropathy care pathways
  • 5.8. Growing emphasis on patient-reported outcomes in clinical trials for IgA nephropathy treatments

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. IgA Nephropathy Market, by Drug Class

  • 8.1. Introduction
  • 8.2. ACE Inhibitors
  • 8.3. Angiotensin Receptor Blockers
  • 8.4. Immunosuppressants
    • 8.4.1. Azathioprine
    • 8.4.2. Corticosteroids
    • 8.4.3. Cyclophosphamide
    • 8.4.4. Mycophenolate mofetil
  • 8.5. Monoclonal Antibodies

9. IgA Nephropathy Market, by Treatment

  • 9.1. Introduction
  • 9.2. Dialysis
  • 9.3. Immunosuppressive Therapy
  • 9.4. Kidney Transplant
  • 9.5. Non-Immunosuppressive Therapy
  • 9.6. Plasmapheresis

10. IgA Nephropathy Market, by Patient Type

  • 10.1. Introduction
  • 10.2. Adults
  • 10.3. Elderly Patients
  • 10.4. Pediatric Patients

11. IgA Nephropathy Market, by End User

  • 11.1. Introduction
  • 11.2. Home Healthcare
  • 11.3. Hospitals
  • 11.4. Research Institutes
  • 11.5. Specialty Clinics

12. IgA Nephropathy Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Offline Pharmacies
    • 12.2.1. Hospital Pharmacies
    • 12.2.2. Retail Pharmacies
  • 12.3. Online Pharmacies

13. Americas IgA Nephropathy Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa IgA Nephropathy Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific IgA Nephropathy Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Alnylam Pharmaceuticals, Inc.
    • 16.3.2. Apellis Pharmaceuticals Inc.
    • 16.3.3. Biogen Inc.
    • 16.3.4. Boehringer Ingelheim International GmbH.
    • 16.3.5. Calliditas Therapeutics AB by Asahi Kasei Corporation
    • 16.3.6. ChemoCentryx, Inc. by Amgen Inc.
    • 16.3.7. Eledon Pharmaceuticals Inc.
    • 16.3.8. Eli Lilly and Company
    • 16.3.9. F. Hoffmann-La Roche Ltd
    • 16.3.10. Ionis Pharmaceuticals Inc
    • 16.3.11. Keymed Biosciences Inc.
    • 16.3.12. Novartis AG
    • 16.3.13. NovelMed Inc.
    • 16.3.14. Novo Nordisk A/S.
    • 16.3.15. Omeros Corporation
    • 16.3.16. Otsuka Pharmaceutical Co. Ltd
    • 16.3.17. Q32 Bio Inc.
    • 16.3.18. Takeda Pharmaceutical Company
    • 16.3.19. Travere Therapeutics Inc
    • 16.3.20. Vera Therapeutics Inc
    • 16.3.21. Vertex Pharmaceuticals Incorporated

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. IGA NEPHROPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL IGA NEPHROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. IGA NEPHROPATHY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. IGA NEPHROPATHY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. IGA NEPHROPATHY MARKET: RESEARCHAI
  • FIGURE 26. IGA NEPHROPATHY MARKET: RESEARCHSTATISTICS
  • FIGURE 27. IGA NEPHROPATHY MARKET: RESEARCHCONTACTS
  • FIGURE 28. IGA NEPHROPATHY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. IGA NEPHROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IGA NEPHROPATHY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IGA NEPHROPATHY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DIALYSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY KIDNEY TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY KIDNEY TRANSPLANT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY NON-IMMUNOSUPPRESSIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY NON-IMMUNOSUPPRESSIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ELDERLY PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ELDERLY PATIENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IGA NEPHROPATHY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 73. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 75. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 87. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 88. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 91. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 92. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 93. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 95. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 96. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 101. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 102. UNITED STATES IGA NEPHROPATHY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 103. CANADA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 104. CANADA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 105. CANADA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 106. CANADA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 107. CANADA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 108. CANADA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 109. CANADA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. CANADA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 111. CANADA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 112. CANADA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 113. CANADA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. CANADA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 115. CANADA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 116. CANADA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 117. MEXICO IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 118. MEXICO IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 119. MEXICO IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 120. MEXICO IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 121. MEXICO IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 122. MEXICO IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 123. MEXICO IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. MEXICO IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. MEXICO IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. MEXICO IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 127. MEXICO IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 128. MEXICO IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 129. MEXICO IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 130. MEXICO IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 131. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 132. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 133. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 134. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 135. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 136. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 137. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 139. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 141. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 143. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 144. BRAZIL IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 145. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 146. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 147. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 148. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 149. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 150. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 151. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 153. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 155. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 157. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 158. ARGENTINA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 177. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED KINGDOM IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 189. GERMANY IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 190. GERMANY IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 191. GERMANY IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 192. GERMANY IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 193. GERMANY IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 194. GERMANY IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 195. GERMANY IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. GERMANY IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 197. GERMANY IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. GERMANY IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 199. GERMANY IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. GERMANY IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 201. GERMANY IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 202. GERMANY IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 203. FRANCE IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. FRANCE IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 205. FRANCE IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 206. FRANCE IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 207. FRANCE IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 208. FRANCE IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 209. FRANCE IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. FRANCE IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 211. FRANCE IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. FRANCE IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. FRANCE IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. FRANCE IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 215. FRANCE IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 216. FRANCE IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 217. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 219. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 220. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 221. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 222. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 223. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 227. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 229. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 230. RUSSIA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 231. ITALY IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. ITALY IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 233. ITALY IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 234. ITALY IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 235. ITALY IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 236. ITALY IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 237. ITALY IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. ITALY IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. ITALY IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. ITALY IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 241. ITALY IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. ITALY IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 243. ITALY IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 244. ITALY IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 245. SPAIN IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. SPAIN IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 247. SPAIN IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 248. SPAIN IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 249. SPAIN IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 250. SPAIN IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 251. SPAIN IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. SPAIN IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 253. SPAIN IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. SPAIN IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 255. SPAIN IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. SPAIN IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 257. SPAIN IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 258. SPAIN IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 261. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 263. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 276. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 278. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 281. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 283. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 285. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 286. SAUDI ARABIA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 288. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 289. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 290. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 291. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 292. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 293. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 297. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 299. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 300. SOUTH AFRICA IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 301. DENMARK IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. DENMARK IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 303. DENMARK IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 304. DENMARK IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 305. DENMARK IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 306. DENMARK IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 307. DENMARK IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. DENMARK IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. DENMARK IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. DENMARK IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 311. DENMARK IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. DENMARK IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 313. DENMARK IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 314. DENMARK IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 315. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 316. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 317. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 318. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 319. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 320. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 328. NETHERLANDS IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 329. QATAR IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 330. QATAR IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 331. QATAR IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 332. QATAR IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 333. QATAR IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 334. QATAR IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 335. QATAR IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. QATAR IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 337. QATAR IGA NEPHROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 338. QATAR IGA NEPHROPATHY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 339. QATAR IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 340. QATAR IGA NEPHROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 341. QATAR IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 342. QATAR IGA NEPHROPATHY MARKET SIZE, BY OFFLINE PHARMACIES, 2025-2030 (USD MILLION)
  • TABLE 343. FINLAND IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 344. FINLAND IGA NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 345. FINLAND IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 346. FINLAND IGA NEPHROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
  • TABLE 347. FINLAND IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 348. FINLAND IGA NEPHROPATHY MARKET SIZE, BY TREATMENT, 2025-2030 (USD MILLION)
  • TABLE 349. FINLAND IGA NEPHROPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 350. FINLAND IG